In focus
Ribo Files EU Clinical Trial Application for Dual-Targeting siRNA SR122 in Dyslipidemia
Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals have submitted a Phase I clinical trial application in the EU for SR122, a dual GalNAc conjugated siRNA targeting ApoC3 and PCSK9 for dyslipidemia. The randomized, placebo-controlled study will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants.
Read the story